Pharma-Bio Serv, Inc. is a compliance and technology transfer services consulting company. The Company operates through four segments: Puerto Rico technical compliance consulting, United States technical compliance consulting, Europe technical compliance consulting, and Puerto Rico microbiological and chemical laboratory testing division (Lab). The Company provides a range of compliance-related consulting services. The Company provides microbiological testing services and chemical testing services through its laboratory testing facility in Puerto Rico. The Company's technical consulting services include regulatory compliance, validation, technology transfer, engineering, project management and process support. The Company markets its services to pharmaceutical, chemical, biotechnology, medical devices, cosmetic and food industries, and allied products companies in Puerto Rico, the United States, Europe and Brazil.
Industry, Sector and Symbol:
- Trailing P/E Ratio:
- Foreward P/E Ratio: 6.15
- P/E Growth:
- Net Margins: -8.23%
- Return on Equity: -6.08%
- Return on Assets: -5.68%
Frequently Asked Questions for Pharma Bio Serv (NASDAQ:PBSV)
What is Pharma Bio Serv's stock symbol?
Pharma Bio Serv trades on the NASDAQ under the ticker symbol "PBSV."
How were Pharma Bio Serv's earnings last quarter?
Pharma Bio Serv Inc (NASDAQ:PBSV) issued its quarterly earnings results on Thursday, January, 29th. The company reported $0.04 EPS for the quarter, beating the Zacks' consensus estimate of $0.03 by $0.01. The company earned $7.14 million during the quarter, compared to the consensus estimate of $7.09 million. Pharma Bio Serv had a negative return on equity of 6.08% and a negative net margin of 8.23%. View Pharma Bio Serv's Earnings History.
When will Pharma Bio Serv make its next earnings announcement?
Who are some of Pharma Bio Serv's key competitors?
Some companies that are related to Pharma Bio Serv include Mid-Con Energy Partners, LP (MCEP), TRACON Pharmaceuticals (TCON), TrovaGene (TROV), Bio-Path Holdings (BPTH), Dimension Therapeutics (DMTX), Ohr Pharmaceuticals (OHRP), Cemtrex (CETX), Presbia PLC (LENS), Medley Management (MDLY), Marrone Bio Innovations (MBII), Microbot Medical (MBOT), Tokai Pharmaceuticals (NVUS), Cesca Therapeutics (KOOL), Threshold Pharmaceuticals (THLD), Pernix Therapeutics Holdings (PTX), Rhino Resource Partners, L.P. (RHNO), Jason Industries (JASN) and Chiasma (CHMA).
Who are Pharma Bio Serv's key executives?
Pharma Bio Serv's management team includes the folowing people:
- Elizabeth Plaza, Chairman of the Board
- Victor Sanchez, President, Chief Executive Officer
- Pedro J. Lasanta, Chief Financial Officer, Vice President - Finance and Administration, Secretary
- Howard Spindel, Independent Director
- Irving L. Wiesen, Independent Director
How do I buy Pharma Bio Serv stock?
Shares of Pharma Bio Serv can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Pharma Bio Serv's stock price today?
MarketBeat Community Rating for Pharma Bio Serv (NASDAQ PBSV)MarketBeat's community ratings are surveys of what our community members think about Pharma Bio Serv and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Pharma Bio Serv stock can currently be purchased for approximately $0.80.
Consensus Ratings for Pharma Bio Serv (NASDAQ:PBSV) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Pharma Bio Serv (NASDAQ:PBSV)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Pharma Bio Serv (NASDAQ:PBSV)Earnings History by Quarter for Pharma Bio Serv (NASDAQ PBSV)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|1/29/2015||$0.03||$0.04||$7.09 million||$7.14 million||View||N/A|
|9/15/2014||$0.02||$0.03||$7.37 million||$6.84 million||View||N/A|
|6/16/2014||$0.05||$0.01||$7.51 million||$6.58 million||View||N/A|
Earnings Estimates for Pharma Bio Serv (NASDAQ:PBSV)
Current Year EPS Consensus Estimate: $0.07 EPS
Next Year EPS Consensus Estimate: $0.13 EPS
Dividend History for Pharma Bio Serv (NASDAQ:PBSV)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Pharma Bio Serv (NASDAQ:PBSV)Insider Trades by Quarter for Pharma Bio Serv (NASDAQ:PBSV)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|2/11/2014||Kirk Wheeler Michel||Director||Sell||9,170||$2.06||$18,890.20|| |
Headline Trends for Pharma Bio Serv (NASDAQ:PBSV)
Latest Headlines for Pharma Bio Serv (NASDAQ:PBSV)
|PBSV: Cash Flow Positive And Trading Below Book Value|
finance.yahoo.com - February 1 at 2:45 PM
|Pharma-Bio Serv Announces Total Net Revenues of $23.4 Million and Net Income of $1.6 Million for the Year Ended October 31, 2015|
finance.yahoo.com - January 29 at 5:13 PM
|PHARMA-BIO SERV, INC. Files SEC form 10-K, Annual Report|
biz.yahoo.com - January 29 at 4:08 PM
|Georgia Bio Deals of the Year Spotlight Financings, Acquisitions and Collaboration|
www.businesswire.com - January 22 at 1:00 PM
|PHARMA-BIO SERV, INC. Files SEC form 8-K, Change in Directors or Principal Officers|
biz.yahoo.com - January 5 at 4:55 PM
|PHARMA-BIO SERV, INC. Financials|
finance.yahoo.com - December 8 at 1:15 PM
|PHARMA-BIO SERV, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits|
biz.yahoo.com - December 1 at 4:54 PM
|Pharma-Bio Serv to Present at the LD Micro Conference on December 2, 2015|
finance.yahoo.com - November 24 at 4:30 PM
|PBSV Returns to Revenue Growth. Maintain Buy Rec|
finance.yahoo.com - September 15 at 3:45 PM
|PHARMA-BIO SERV, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh|
biz.yahoo.com - September 14 at 5:10 PM
|Pharma-Bio Serv Announces Results for the Three and Nine Months Ended July 31, 2015|
finance.yahoo.com - September 14 at 4:30 PM
|PHARMA-BIO SERV, INC. Files SEC form 10-Q, Quarterly Report|
biz.yahoo.com - September 14 at 4:24 PM
|Pharma-Bio Serv to Present at the Sidoti Emerging Growth Conference|
finance.yahoo.com - August 31 at 4:58 PM
|PBSV: Q2 EPS Inline, New Revenue Catalysts in Pipeline|
finance.yahoo.com - June 16 at 1:45 PM
Pharma Bio Serv (PBSV) Chart for Wednesday, July, 26, 2017